^
    Back
    Association details:
    Biomarker:HER-2 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) +
    Cipterbin (inetetamab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer

    Excerpt:
    ...Histologically or cytologically documented metastatic NSCLC, HER2 activation amplification or mutation stage IIIB-IV NSCLC patient; 3....
    Trial ID:
    NCT05016544
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial.

    Published date:
    05/25/2023
    Excerpt:
    This study was an open-label, phase Ib study. The HER2 mutant patients with locally advanced or metastatic NSCLC were assigned to receive inetetamab combined with pyrotinib….The ORR and DCR of inetetamab with pyrotinib 320mg group were 36.6% and 85.4% respectively.
    DOI:
    10.1200/JCO.2023.41.16_suppl.9105
    Trial ID:
    NCT05016544